PET-CT en pacientes con melanoma cutáneo maligno

Acosta ÁE, Fierro E, Velásquez VE, Rueda X. Melanoma: patogénesis, clínica e histopatología. Rev Asoc Col Dermatol. 2009;17(2):87-108.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.

https://doi.org/10.3322/caac.20006

National Comprehensive Cancer Network Melanoma. Melanoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004;2(1):46-60.

https://doi.org/10.6004/jnccn.2004.0003

Roldán L, Lopera M, Suaza G. Melanoma lentiginoso acral: una variante de melanoma maligno de especial interés en Colombia. Rev Fac Med Univ. Antioquia. 2008;21(4):386-97.

Nestle FO, Halpern AC. Neoplasms of the skin: Melanoma. En: Bolognia J, Jorizzo JL, Rapini RP, editores. Dermatology. 2a ed. Madrid: Mosby; 2008. p. 1745-69.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 database: fast stats [Internet]. Lyon, France: International Agency for Research on Cancer 2010 [Citado: 8 julio 2010]. Disponible en: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#BOTH.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Jun 17.

https://doi.org/10.1002/ijc.25516

National Cancer Institute, Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Melanoma of the Skin [Internet]. Bethesda, MD: National Cancer Institute; 2009 [Citado: 8 julio 2010]. Disponible en: http://seer.cancer.gov/statfacts/html/melan.html.

Colombia, Instituto Nacional de Cancerología. Registro Institucional de Cáncer. En: Anuario Estadístico 2008. Bogotá: INC; 2009. p. 11-13.

Jiménez-Requena F, Delgado-Bolton RC, Fernández-Pérez C, Gambhir SS, Schwimmer J, Pérez-Vázquez JM, et al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging. 2010;37(2):284-300.

https://doi.org/10.1007/s00259-009-1224-8

Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24(7):1178-87.

https://doi.org/10.1200/JCO.2005.03.5634

Kell MR, Ridge JA, Joseph N, Sigurdson ER. PET-CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur J Surg Oncol. 2007;33(7):911-3.

https://doi.org/10.1016/j.ejso.2006.11.016

Iagaru A, Quon A, Johnson D, Gambhir SS, McDougall IR. 2-Deoxy-2-[F-18] uoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol. 2007;9(1):50-7.

https://doi.org/10.1007/s11307-006-0065-0

Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun. 2007;28(4):273-80.

https://doi.org/10.1097/MNM.0b013e3280708ecf

Mottaghy F, Sunderkötter C, Schubert R, Wohlfart P, Blumstein NM, Neumaier B, et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging. 2007;34(9):1355-64.

https://doi.org/10.1007/s00259-006-0358-1

Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F- uorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer. 2007;43(3):557-64.

https://doi.org/10.1016/j.ejca.2006.11.014

Strobel K, Dummer R, Husarik DB, Pérez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007;244(2):566-74.

https://doi.org/10.1148/radiol.2442061099

Singh B, Ezziddin S, Palmedo H, Reinhardt M, Strunk H, Tüting T, et al. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res. 2008;18(5):346-52.

https://doi.org/10.1097/CMR.0b013e32830b363b

Veit-Haibach P, Vogt FM, Jablonka R, Kuehl H, Bockisch A, Beyer T, et al. Diagnostic accuracy of contrastenhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging. 2009;36(6):910-8.

https://doi.org/10.1007/s00259-008-1049-x

Klode J, Dissemond J, Grabbe S, Hillen U, Poeppel T, Boeing C. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II. Dermatol Surg. 2010;36(4):439-45.

https://doi.org/10.1111/j.1524-4725.2010.01479.x

Römer W, Nömayr A, Greess H, Fiedler E, Platsch G, Schuler-Thurner B, et al. Retrospective interactive rigid fusion of (18)F-FDG-PET and CT. Additional diagnostic information in melanoma patients. Nuklearmedizin. 2006;45(2):88-95.

https://doi.org/10.1055/s-0038-1625738

Akcali C, Zincirkeser S, Erbagcý Z, Akcali A, Halac M, Durak G, et al. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. J Int Med Res. 2007;35(4):547-53.

https://doi.org/10.1177/147323000703500415

Niederkohr RD, Rosenberg J, Shabo G, Quon A. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma. Nucl Med Commun. 2007;28(9):688-95.

https://doi.org/10.1097/MNM.0b013e32827420cc

Strobel K, Skalsky J, Steinert HC, Dummer R, Hany TF, Bhure U, et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology. 2007;215(3):192-201.

https://doi.org/10.1159/000106575

Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, et al. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging. 2008;35(10):1786-95.

https://doi.org/10.1007/s00259-008-0806-1

Constantinidou A, Hofman M, O'Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited bene t. Melanoma Res. 2008;18(1):56-60.

https://doi.org/10.1097/CMR.0b013e3282f62404